Inventory of listing, financing and mergers and acquisitions in the biomedical field in 2019

·In 2019, 43 biopharmaceutical companies were listed, raising 36.24 billion yuan in total; in 2019, there were 857 financing events in China's biopharmaceutical field, with a total financing amount of 111.56 billion yuan, the financing rounds were mainly concentrated in round a, and the cities were mainly concentrated in Beijing, Shanghai and Hangzhou; ·In 2019, there were 609 M & A events in China's biomedical sector, with a total financing amount of 109.548 billion yuan, and the main board's M & a performance was the most active According to the database of Huoshi creation, 43 enterprises were listed in the field of biomedicine in 2019, with a total amount of 36.24 billion yuan raised 1 Number of Listings: 15 listed on Shanghai Stock Exchange (14 on science and technology innovation board, 1 on main board), 3 listed on Shenzhen Stock Exchange (2 on growth enterprise board, 1 on small and medium-sized board), 11 listed on agent transfer market, 12 listed on Hong Kong stock exchange, and 2 listed on American Nasdaq Stock Exchange Among them, KANGLONG Huacheng was listed on the growth enterprise market of Shenzhen Stock Exchange and Hong Kong Stock Exchange on January 28, 2019 and November 28, 2019, respectively It is the only bio pharmaceutical enterprise that has achieved multi listing in 2019 2 The financing amount is RMB 11.835 billion from the initial public offering of Shanghai Stock Exchange, RMB 1.758 billion from Shenzhen Stock Exchange, RMB 21.452 billion from Hong Kong stock exchange, and RMB 598 million from Nasdaq Stock Exchange of the United States See Table 1 Table 1 data source of listing of biomedical enterprises in 2019: by the end of 2019, there were 874 biomedical enterprises listed in China, with the raised capital of 252.09 billion yuan Among them, there are 197 Shenzhen stock exchanges (38 main boards, 84 growth enterprises and 75 small and medium-sized boards), raising 97.58 billion yuan According to the Huoshi creation database, 117 Shanghai stock exchanges (14 science and technology innovation boards and 103 mainboards) have raised 51.78 billion yuan, 504 stock exchanges have been listed, 58 Hong Kong stock exchanges have been listed, and 99.31 billion yuan has been raised The total number of the three major exchanges in the United States is 11, with 3.43 billion yuan in total Figure 1 listing quantity and financing situation of national bio medicine in each exchange market (Note: exchange rate is converted by listing on the same day) financing situation of bio medicine in 2019 According to Huoshi creation database, in 2019, there were 857 financing events in China's biomedical field, with a total financing amount of RMB 111.56 billion; the financing rounds were mainly in round a; the cities were mainly in Beijing, Shanghai and Hangzhou 1 Distribution of financing rounds in the field of biomedicine in 2019 is mainly round a financing, with a total of 308 financing rounds, with a financing amount of 26.27 billion yuan; followed by strategic financing, with a total of 166 financing rounds, with a financing amount of 48.47 billion yuan; Figure 2 financing rounds and amounts of Biomedical enterprises in 2019 2 Urban distribution In 2019, financing events are mainly concentrated in Beijing, Shanghai and Hangzhou, with 192, 179 and 65 events respectively In terms of financing amount, although Nantong and Changchun have financing amount of 6 and 2 respectively, the financing amount has reached 7.56 billion yuan and 5.637 billion yuan respectively, ranking third and fourth in the city Figure 3 distribution of some cities in 2019 biomedical enterprise financing Table 2 top 10 financing amount of biomedical enterprises in 2019 note: the strategic financing stage will be eliminated in 2019 According to the Huoshi creation database, there are 609 M & A events in China's biomedical field in 2019, with a total financing amount of 109.548 billion yuan, and the main board's M & a performance is the most active 1 Transaction progress: in 2019, there were 609 M & A events in China's biomedical sector, involving a total amount of 109.548 billion yuan, including 366 ongoing M & A events, involving a total amount of 52.839 billion yuan, 230 completed M & A events, involving a total amount of 54.861 billion yuan, 13 failed M & A events, involving a total amount of 1.848 billion yuan Figure 4 progress of biomedical M & A in 2019 2 After the failure events are eliminated in the listing sector, the current main board M & A events are the most active in terms of both the number of M & A and the amount involved In the whole year, the main board involved 205 M & A events, involving a total amount of RMB 64.063 billion; the new third board involved only RMB 2.719 billion although the number of M & A events was 195; the gem involved 118 M & A events, involving a total amount of RMB 16.219 billion; the SME board involved 78 M & A events, involving a total amount of RMB 24.999 billion Figure 5 2019 distribution of biomedical M & A and listing plate 3 Field distribution: the most active M & A in chemical pharmaceutical field, with 148 M & A events involving 28.247 billion yuan; the least involved M & A events in medical device field, though frequent, involving 7.741 billion yuan; 98 M & A events in traditional Chinese Medicine II field, involving 13.553 billion yuan Figure 6 the distribution of biomedical M & A in 2019 4 See Table 3 for the top 10 companies involved in M & A in the biomedical industry in 2019 Table 3 top 10 amount of M & A of biomedical enterprises in 2019 original title: inventory of listing, financing and M & A of biomedical enterprises in 2019